Literature DB >> 9855625

Naturally occurring analogs of lysophosphatidic acid elicit different cellular responses through selective activation of multiple receptor subtypes.

D J Fischer1, K Liliom, Z Guo, N Nusser, T Virág, K Murakami-Murofushi, S Kobayashi, J R Erickson, G Sun, D D Miller, G Tigyi.   

Abstract

Lysophosphatidic acid (LPA), plasmalogen-glycerophosphate (alkenyl-GP) and, cyclic-phosphatidic acid (cyclic-PA) are naturally occurring phospholipid growth factors (PLGFs). PLGFs elicit diverse biological effects via the activation of G protein-coupled receptors in a variety of cell types. In NIH3T3 fibroblasts, LPA and alkenyl-GP both induced proliferation, whereas cyclic-PA was antiproliferative. LPA and alkenyl-GP decreased cAMP in a pertussis toxin-sensitive manner, whereas cyclic-PA caused cAMP to increase. LPA and alkenyl-GP both stimulated the activity of the mitogen-actived protein kinases extracellular signal regulated kinases 1 and 2 and c-Jun NH2-terminal kinase, whereas cyclic-PA did not. All three PLGFs induced the formation of stress fibers in NIH3T3 fibroblasts. To determine whether these lipids activated the same or different receptors, heterologous desensitization patterns were established among the three PLGFs by monitoring changes in intracellular Ca2+ in NIH3T3 fibroblasts. LPA cross-desensitized both the alkenyl-GP and cyclic-PA responses. Alkenyl-GP cross-desensitized the cyclic-PA response, but only partially desensitized the LPA response. Cyclic-PA only partially desensitized both the alkenyl-GP and LPA responses. We propose that pharmacologically distinct subsets of PLGF receptors exist that distinguish between cyclic-PA and alkenyl-GP, but are all activated by LPA. We provide evidence that the PSP24 receptor is selective for LPA and not activated by the other two PLGFs. RT-PCR and Northern blot analysis indicate the co-expression of mRNAs encoding the EDG-2, EDG-4, and PSP24 receptors in a variety of cell lines and tissues. However, the lack of mRNA expression for these three receptors in the LPA-responsive Rat-1 and Sp2-O-Ag14 cells suggests that a number of PLGF receptor subtypes remain unidentified.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9855625     DOI: 10.1124/mol.54.6.979

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  19 in total

1.  Anatomical location of LPA1 activation and LPA phospholipid precursors in rodent and human brain.

Authors:  Estibaliz González de San Román; Iván Manuel; María Teresa Giralt; Jerold Chun; Guillermo Estivill-Torrús; Fernando Rodríguez de Fonseca; Luis Javier Santín; Isidro Ferrer; Rafael Rodríguez-Puertas
Journal:  J Neurochem       Date:  2015-04-27       Impact factor: 5.372

2.  Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis.

Authors:  Daniel L Baker; Yuko Fujiwara; Kathryn R Pigg; Ryoko Tsukahara; Susumu Kobayashi; Hiromu Murofushi; Ayako Uchiyama; Kimiko Murakami-Murofushi; Eunjin Koh; Russell W Bandle; Hoe-Sup Byun; Robert Bittman; Dominic Fan; Mandi Murph; Gordon B Mills; Gabor Tigyi
Journal:  J Biol Chem       Date:  2006-06-16       Impact factor: 5.157

Review 3.  Lysophosphatidic acid type 2 receptor agonists in targeted drug development offer broad therapeutic potential.

Authors:  Gabor J Tigyi; Leonard R Johnson; Sue Chin Lee; Derek D Norman; Erzsebet Szabo; Andrea Balogh; Karin Thompson; Alyssa Boler; W Shannon McCool
Journal:  J Lipid Res       Date:  2019-01-28       Impact factor: 5.922

4.  Assessment of agonism at G-protein coupled receptors by phosphatidic acid and lysophosphatidic acid in human embryonic kidney 293 cells.

Authors:  F Alderton; B Sambi; R Tate; N J Pyne; S Pyne
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

5.  Rho Kinase Regulation of Fibroblast Migratory Mechanics in Fibrillar Collagen Matrices.

Authors:  Chengxin Zhou; W Matthew Petroll
Journal:  Cell Mol Bioeng       Date:  2010-03-01       Impact factor: 2.321

Review 6.  Phosphatase-resistant analogues of lysophosphatidic acid: agonists promote healing, antagonists and autotaxin inhibitors treat cancer.

Authors:  Glenn D Prestwich; Joanna Gajewiak; Honglu Zhang; Xiaoyu Xu; Guanghui Yang; Monica Serban
Journal:  Biochim Biophys Acta       Date:  2008-04-08

7.  Transforming growth factor-beta1 (TGFbeta1) stimulates connective tissue growth factor (CCN2/CTGF) expression in human gingival fibroblasts through a RhoA-independent, Rac1/Cdc42-dependent mechanism: statins with forskolin block TGFbeta1-induced CCN2/CTGF expression.

Authors:  Samuel A Black; Philip C Trackman
Journal:  J Biol Chem       Date:  2008-02-20       Impact factor: 5.157

8.  The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury.

Authors:  Wenlin Deng; E Shuyu; Ryoko Tsukahara; William J Valentine; Gangadhar Durgam; Veeresa Gududuru; Louisa Balazs; Venkatraman Manickam; Marcello Arsura; Lester VanMiddlesworth; Leonard R Johnson; Abby L Parrill; Duane D Miller; Gabor Tigyi
Journal:  Gastroenterology       Date:  2007-03-24       Impact factor: 22.682

9.  Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation.

Authors:  Jesica R Williams; Anna L Khandoga; Pankaj Goyal; James I Fells; Donna H Perygin; Wolfgang Siess; Abby L Parrill; Gabor Tigyi; Yuko Fujiwara
Journal:  J Biol Chem       Date:  2009-04-14       Impact factor: 5.157

10.  Subtype-specific residues involved in ligand activation of the endothelial differentiation gene family lysophosphatidic acid receptors.

Authors:  William J Valentine; James I Fells; Donna H Perygin; Sana Mujahid; Kazuaki Yokoyama; Yuko Fujiwara; Ryoko Tsukahara; James R Van Brocklyn; Abby L Parrill; Gabor Tigyi
Journal:  J Biol Chem       Date:  2008-03-03       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.